MA47729A - Inhibiteurs de bêta-sécrétase - Google Patents

Inhibiteurs de bêta-sécrétase

Info

Publication number
MA47729A
MA47729A MA047729A MA47729A MA47729A MA 47729 A MA47729 A MA 47729A MA 047729 A MA047729 A MA 047729A MA 47729 A MA47729 A MA 47729A MA 47729 A MA47729 A MA 47729A
Authority
MA
Morocco
Prior art keywords
beta
secretase inhibitors
secretase
inhibitors
Prior art date
Application number
MA047729A
Other languages
English (en)
Inventor
Sathesh Pangala Bhat
Henricus Jacobus Maria Gijsen
Daniel Oehlrich
Den Keybus Frans Alfons Maria Van
Ann Marleen Vos
Karl Shawn Watts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47729A publication Critical patent/MA47729A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA047729A 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase MA47729A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468052P 2017-03-07 2017-03-07
EP17189762 2017-09-07

Publications (1)

Publication Number Publication Date
MA47729A true MA47729A (fr) 2020-01-15

Family

ID=61616993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047729A MA47729A (fr) 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase

Country Status (9)

Country Link
US (1) US20200010482A1 (fr)
EP (1) EP3592750A1 (fr)
JP (1) JP2020509068A (fr)
KR (1) KR20190126345A (fr)
CN (1) CN110418793A (fr)
AU (1) AU2018229721A1 (fr)
CA (1) CA3051764A1 (fr)
MA (1) MA47729A (fr)
MX (1) MX2019010649A (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JPWO2011071109A1 (ja) * 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
US9556135B2 (en) * 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use

Also Published As

Publication number Publication date
EP3592750A1 (fr) 2020-01-15
KR20190126345A (ko) 2019-11-11
JP2020509068A (ja) 2020-03-26
AU2018229721A1 (en) 2019-08-15
MX2019010649A (es) 2019-10-21
US20200010482A1 (en) 2020-01-09
CA3051764A1 (fr) 2018-09-13
CN110418793A (zh) 2019-11-05

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3731771T3 (da) V462033dk00
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
MA52812A (fr) Inhibiteurs de sarm1
DE202018003363U8 (de) Handgelenkssphygmomanometer
DK3672976T3 (da) Bcl-2-hæmmere
CL2018000524S1 (es) Golilla
MA46857A (fr) Inhibiteurs de magl
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3681884T3 (da) Rad51-inhibitorer
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
MA46860A (fr) Inhibiteurs de magl
DK3351526T3 (da) Diisopentylterephthalat
MA46855A (fr) Inhibiteurs de magl
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
MA52813A (fr) Inhibiteurs de sarm1
DK3568655T3 (da) Rekuperator
MA52809A (fr) Inhibiteurs de sarm1
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3612237T3 (da) Genterapi